Business & Industry
Business & Industry
Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal
Teva Pharmaceuticals has entered into a definitive agreement to acquire Emalex Biosciences, strengthening its neuroscience pipeline through the addition of ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome. The move reinforces the companyโs strategic shift toward innovation-led expansion,...
BioPharma
Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026
Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion...
Business & Industry
FDA Issues 3 Priority Vouchers for Psychedelic Drug Firms
The US Food and Drug Administration has awarded three additional Commissioner's National Priority Vouchers under its accelerated regulatory framework, targeting companies developing psychedelic-based therapies. The move follows President Donald Trumpโs April 18 executive order aimed at advancing mental health...
Business & Industry
MSD Google Cloud Partnership Drives AI Adoption at Scale
MSD has entered into a multi-year agreement with Google Cloud valued at up to $1 billion, enabling widespread deployment of advanced artificial intelligence tools across its global workforce of 75,000 employees. The collaboration will integrate Google Cloudโs agentic AI...
BioPharma
The Hidden Cost of Licensing in Biologic Drug Development
Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
Business & Industry
AbbVie to Invest $1.4B in North Carolina Manufacturing Plant
AbbVie has outlined plans to build a major new manufacturing facility in Durham, committing $1.4 billion to what will become its largest single-campus capital investment to date. The project, spread across 185 acres, is expected to generate more than...
BioPharma
Trump Order Targets Faster Psychedelic Drug Reviews by FDA
The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















